Rubidium chloride
As of the edition of 20 October 2026, Rubidium chloride is a small molecule: marketed, first approved in 1989 (US); no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1989
- Kind
- Small molecule
- Brand name
- CARDIOGEN-82
- First approved
- 29 December 1989 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Jubilant DraxImage; 2 holders in all
- Registered trials
- 2, 0 stopped early
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| All trials | 2 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Bristol Myers Squibb | Earlier holder | 1989 to now |
| Bracco Diagnostics | Acquired holder and Lead sponsor of trials | 2003 to now |
| Jubilant DraxImage | Later holder | 2016 to now |